Our Company: Developing Oncology Therapeutics to Improve Cancer Care
Our lead therapeutic candidate, PCM-075, provides us the opportunity to bring a first-in-class PLK1 inhibitor to the market for the treatment of patients with acute myeloid leukemia (AML). The pharmacokinetic and pharmacodynamic properties of PCM-075 may provide a more selective approach for targeting the rapid mitosis that is characteristic of AML, as well as avoid some of the debilitating toxicities seen with standard chemotherapy drugs.
What are the Key Statistics About AML?
The American Cancer Society’s estimates for leukemia in the United States for 2017 are:
- About 21,380 new cases of acute myeloid leukemia (AML). Most will be in adults.
- About 10,590 deaths from AML. Almost all will be in adults.
Coming Soon NextCollect™
NextCollect™ is a first of its kind, proprietary urine collection and DNA preservation system. By housing the preservative solution in the reservoir cap, we have created the first ever automated DNA stabilizing device for urine collection. For more information, please email email@example.com.
Marcum 2017 MicroCap Conference
Trovagene CEO, Bill Welch, will be presenting at the conference on Thursday, June 15th, at 3:00 pm EDT at the Grand Hyatt Hotel in NY. The presentation will be webcast live at http://wsw.com/webcast/marcum5/trov and a replay of the presentation will be available and archived for 90 days.